NewsBite

Why Chris Kourtis just bought CSL and ResMed

Joshua PeachMarkets reporter

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

A true contrarian investor, Chris Kourtis can find himself sounding a lot like a bull when in the company of bears, and there’s a lot to be bearish about at the moment.

“When you put it in the melting pot very slow global growth, very high and sticky stagflation against a backdrop of the geopolitical environment, it’s a time to be cautious,” he tells The Australian Financial Review.

Loading...
Joshua Peach is a Markets Reporter at The Australian Financial Review Email Joshua at joshua.peach@nine.com.au

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Latest In Equity markets

Fetching latest articles

Most Viewed In Markets

    Original URL: https://www.afr.com/markets/equity-markets/why-chris-kourtis-just-bought-csl-and-resmed-20231101-p5egon